Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus interdum dui velit, sed porta massa convallis et. Integer sed neque posuere arcu blandit hendrerit. Nullam sed maximus nulla, sed elementum dui. Integer sed lacinia massa. Nunc felis nibh, lacinia vitae augue eget, tristique facilisis neque.
NervGen’s core technology was developed in the laboratory of Dr. Jerry Silver, a renowned spinal cord injury and regenerative medicine researcher and Professor of Neurosciences at Case Western Reserve University (CWRU) in Cleveland, Ohio. Dr. Silver’s research focuses on the glial scar which forms at sites of a physical injury such as spinal cord injury, as well as sites of inflammatory damage from neurodegenerative diseases such as multiple sclerosis and Alzheimer’s disease.
Injury or disease to the central nervous system (CNS) results in multifaceted cellular and molecular responses. One such response, the glial scar, is a structural formation of reactive glia (cells) around an area of severe tissue damage. The purpose of the scar is to encapsulate the site of the injury to prevent further damage and begin the healing process, but it ultimately inhibits the body’s reparative mechanisms. The lead inventor of NervGen’s technology, Dr. Silver, discovered that a constituent of these scars, a glycoprotein called chondroitin sulfate proteoglycan (“CSPG”), is a major inhibitor of the body’s natural ability to regrow and regenerate the CNS.
Dr. Silver, together with scientists at Harvard University, identified protein tyrosine phosphatase sigma (“PTPσ”) as a key neural receptor that binds with the CSPGs in the glial scar (Shen et al., 2009, Science). Dr. Silver’s research showed that PTPσ impedes nerve regeneration through its activation upon binding to CSPGs in the glial scar.
Multiple studies with animal models for several diseases and medical conditions have shown that treatment targeting PTPσ receptors with a compound developed by Dr. Silver and his research team, NVG-291-R (also called intracellular sigma peptide, or ISP in publications), promoted regeneration of damaged nerves and improvement in function (Lang et al., 2015, Nature; Gardner et al., 2015, Nature Communications; Li, H., 2015, Scientific Reports; Rink et al., 2018, Experimental Neurology; Luo et al. 2018, Nature Communications ). NervGen licenced the intellectual property underpinning this research from Case Western Reserve University and is now developing NVG-291-R as the basis for its core technology. NervGen’s lead product, NVG-291, is a close analog to NVG-291-R.
Since the original discovery of NVG-291-R, the compound has been studied further by Dr. Silver and his collaborators, by NervGen and by a number of independent laboratories. There is now a large body of evidence to indicate that NVG-291-R’s mechanism for nerve repair is mediated by a number of endogenous repair mechanisms, including regeneration, plasticity, remyelination, immune modulation and synapse formation. Furthermore, these repair mechanisms seem to be helpful in treating nerve damage associated with both nerve injury (spinal cord injury, peripheral nerve injury, traumatic brain injury, and stroke) and with neurodegenerative diseases (multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson’s disease).
NervGen’s initial development programs are focusing on spinal cord injury, multiple sclerosis and Alzheimer’s disease.
A list of select scientific publications that give a robust overview of the effects of NVG-291-R seen in animal models is provided in Notitia – Our Data Center
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com